NPCE - NeuroPace Inc

QQQ $ 452.83 $ 6.97 (1.56 %)

DIA $ 399.31 $ 3.70 (0.94 %)

SPY $ 529.09 $ 6.48 (1.24 %)

TLT $ 92.14 $ 1.24 (1.36 %)

GLD $ 220.89 $ 2.80 (1.28 %)

Previous Close

$ 9.03

Open

$ 8.73

Bid

$ 8.99 x 123

Ask

$ 17.00 x 100

Day's Range

$ 8.57 - $ 9.11

52 Week Range

$ 3.80 - $ 18.15

Volume

151,685

Average Volume

Market Cap

255.42M

Beta (5Y Monthly)

$ 1.34

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-08-2024	03-31-2024	10-Q
2	03-05-2024	12-31-2023	10-K
3	11-06-2023	09-30-2023	10-Q
4	08-08-2023	06-30-2023	10-Q
5	05-04-2023	03-31-2023	10-Q
6	03-02-2023	12-31-2022	10-K
7	11-08-2022	09-30-2022	10-Q
8	08-11-2022	06-30-2022	10-Q
9	05-12-2022	03-31-2022	10-Q
10	03-10-2022	12-31-2021	10-K
11	11-10-2021	09-30-2021	10-Q
12	08-12-2021	06-30-2021	10-Q
13	06-03-2021	03-31-2021	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

12-health-care-stocks-moving-in-thursdays-intraday-session

12 Health Care Stocks Moving In Thursday's...
05/09/2024 16:31:09

Cantor Fitzgerald Reiterates Overweight on...
05/09/2024 15:09:33

Cantor Fitzgerald analyst Ross Osborn reiterates NeuroPace (NASDAQ:NPCE) with a Overweight and maintains $18 price target.

NeuroPace Maintains FY24 Revenue Guidance ...
05/08/2024 21:23:05

Gross margin to range between 72% and 74%, Total operating expenses to range between $80 million and $84 million, including app...

NeuroPace Q1 2024 GAAP EPS $(0.32) Beats $...
05/08/2024 20:26:15

NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by ...

Wells Fargo Upgrades NeuroPace to Overweig...
03/14/2024 13:18:38

Wells Fargo analyst Lawrence Biegelsen upgrades NeuroPace (NASDAQ:NPCE) from Equal-Weight to Overweight and raises the price...

The Latest Analyst Ratings For NeuroPace
03/12/2024 14:00:46

JP Morgan Maintains Overweight on NeuroPac...
03/12/2024 13:07:31

JP Morgan analyst Robbie Marcus maintains NeuroPace (NASDAQ:NPCE) with a Overweight and raises the price target from $9 to $17.

Cantor Fitzgerald Maintains Overweight on ...
03/06/2024 17:28:17

Cantor Fitzgerald analyst Ross Osborn maintains NeuroPace (NASDAQ:NPCE) with a Overweight and raises the price target from $...

Morgan Stanley Maintains Equal-Weight on N...
03/06/2024 17:15:12

Morgan Stanley analyst Drew Ranieri maintains NeuroPace (NASDAQ:NPCE) with a Equal-Weight and raises the price target from $...

NeuroPace Provides Full-year 2024 Revenue ...
03/05/2024 22:28:00

Gross margin to range between 72% and 74%, Total operating expenses to range between $80 million and $84 million, including app...

Recap: NeuroPace Q4 Earnings
03/05/2024 21:35:06

NeuroPace Q4 2023 GAAP EPS $(0.23) Beats $...
03/05/2024 21:32:58

NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.32) by ...

Earnings Scheduled For March 5, 2024
03/05/2024 10:00:02

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2...

Earnings Preview: NeuroPace
03/04/2024 17:01:14

A Glimpse Into The Expert Outlook On Neuro...
02/22/2024 17:00:36

NeuroPace Stock: A Deep Dive Into Analyst ...
01/30/2024 14:00:14

Leerink Partners Initiates Coverage On Neu...
01/30/2024 13:15:02

Leerink Partners analyst Mike Kratky initiates coverage on NeuroPace (NASDAQ:NPCE) with a Outperform rating and announces Pr...

NeuroPace Sees Prelim. Q4 Revenue $17.5M-$...
01/08/2024 12:30:16

Breaking Down NeuroPace: 6 Analysts Share ...
12/27/2023 15:00:24

Lake Street Reiterates Buy on NeuroPace, M...
12/27/2023 14:29:32

Lake Street analyst Frank Takkinen reiterates NeuroPace (NASDAQ:NPCE) with a Buy and maintains $12 price target.